OINDP specialist CDMOs Bespak and Upperton have announced a new strategic collaboration that will offer services based on Upperton’s UpperNose nasal development platform and manufacturing capability in conjunction with Bespak nasal delivery devices. The announcement cites growing demand, particularly for intranasal CNS and nose-to-brain therapies, and the need for more efficient development from early development through to commercial manufacturing as a motive for the partnership.
According to the companies, the services will be available for a wide range of nasal formulations, including liquid, dry powder, and soft mist for delivery via single or multi-dose devices. Bespak (then Recipharm) and Medspray announced in January 2024 that their joint venture Resyca would develop soft mist nasal devices in addition to soft mist inhalers.
Bespak CEO Chris Hirst commented, “Nasal drug delivery is an exciting and rapidly evolving area, particularly as developers explore new opportunities for systemic delivery of CNS therapies and innovative nose-to-brain applications. However, successful development requires formulation, device and manufacturing strategies to work together from the outset. Our collaboration with Upperton adds highly complementary formulation and analytical expertise to our expanded nasal device portfolio, giving customers a more integrated development pathway. By considering the formulation and device as one combination product from an early stage, we can help customers navigate development more efficiently and build a stronger foundation for clinical and commercial success.”
Upperton CEO Nikki Whitfield said, “Successful nasal drug product development depends on a detailed understanding of the interaction between formulation, device, and manufacturing requirements. By combining Upperton’s formulation, analytical and clinical manufacturing expertise with Bespak’s device engineering and commercialization capabilities, we can provide customers with coordinated support across the development journey. Bringing our specialists together around each program will help customers make critical development decisions earlier and provide a clearer pathway from development and clinical supply towards commercialization.”
Read the Bespak press release
